Other languages Eagle Pharmaceuticals, Inc.

Equities

EGRX

US2697961082

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
3.47 ^USD	+1.31%		-7.22%	-33.65%

May. 15	Eagle Pharmaceuticals, Inc. Enters into a Third Amendment to Third Amended and Restated Credit Agreement	CI
May. 06	North American Morning Briefing : Stock Futures -2-	DJ

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq	May. 22
Eagle Pharmaceuticals, Inc. Enters into a Third Amendment to Third Amended and Restated Credit Agreement	May. 15
North American Morning Briefing : Stock Futures -2-	May. 06
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting	Apr. 30
North American Morning Briefing : Investors Brace -2-	Apr. 29
North American Morning Briefing : Stock Futures -2-	Apr. 22
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting	Apr. 16
Sector Update: Health Care Stocks Softer Late Afternoon	Apr. 15
Sector Update: Health Care	Apr. 15
Eagle Pharmaceuticals Says Phase 3 Data Show Amisulpride's Sustained Antiemetic Effect; Shares Rise	Apr. 15
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K	Apr. 15
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida	Apr. 15
North American Morning Briefing : Stock Futures -2-	Apr. 15
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting at the Upcoming ASPAN 2024 National Conference in Orlando, Florida	Apr. 14
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K	Apr. 12
North American Morning Briefing : Inflation Data, -2-	Apr. 08
North American Morning Briefing : Tech in Focus on -2-	Mar. 25
North American Morning Briefing : Investors -2-	Mar. 18
Sector Update: Health Care Stocks Softer Late Afternoon	Mar. 11
Sector Update: Health Care	Mar. 11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Eagle Pharmaceuticals, Inc.

Equities

EGRX

US2697961082

Other languages

Filters